Summary To date, cytogenetic studies on pancreatic carcinoma are rare, and little is known about the frequency of cytogenetic aberrations in primary carcinomas compared with metastatic tumour cells. We therefore evaluated the frequency of chromosomal aberrations in 12 primary pancreatic carcinomas and in effusion specimens from 25 patients with pancreatic cancer by using interphase fluorescence in situ hybridization (FISH) and a panel of four centromeric probes. Hyperdiploidy and chromosomal imbalances, predominantly affecting chromosome 8, were a constant finding in metastatic effusion cells, whereas concordant gain of chromosomes or relative loss of chromosome 18 characterized primary pancreatic carcinomas. The potential role of oncogenes located on chromosome 8 for pancreatic cancer progression was further investigated by double-hybridization studies of aneuploid effusion cells with a probe to 8q24 (MYC) and a centromeric probe to chromosome 8, which demonstrated amplification of the MYC oncogene in two of ten cases (20%). Finally, a potential application of basic findings in the clinical setting was tested by searching for micrometastatic cells in effusions from pancreatic cancer patients primarily negative by FISH. Two-colour FISH in combination with extensive screening (>10 000 nuclei) seems to be a useful tool to unequivocally identify micrometastatic cells by demonstrating hyperdiploidy and intranuclear chromosomal heterogeneity.
So far, 90 exocrine and endocrine pancreatic cancers have been karyotyped successfully (larger series on exocrine pancreatic carcinoma: Johansson et al, 1992; Bardi et al, 1993; Griffin et al, 1994 Griffin et al, , 1995  smaller series or case reports on exocrine or endocrine pancreatic tumours: van der Riet-Fox et al, 1979; Bullerdiek et al, 1985; Casalone et al, 1987; Teyssier, 1987; Scappaticci et al, 1992; Bardi et al, 1994; Bugalho et al, 1994; Danner et al, 1994; Gorunova et al, 1995; Wiley et al, 1995; Grant et al, 1996) . Considering the data available, loss of chromosome 18 is the most common numerical aberration identified by metaphase cytogenetics, occurring in half of the exocrine tumours with an abnormal karyotype. By comparative genomic hybridization, Solinas-Toldo et al (1996) demonstrated loss on 18q in 3 of 27 exocrine pancreatic cancers and Fukushige et al (1997) in five of six primary carcinomas and 10 of 12 cell lines. Recently, the tumour-suppressor gene DPC4 was identified as the primary target of these aberrations (Hahn et al, 1996) .
Besides chromosome 18, numerical aberrations in exocrine pancreatic tumours were reported to frequently involve chromosomes 7, 11, 12 and 20. Fluorescence in situ hybridization (FISH) with chromosome-specific probes can be used to visualize chromosomal aberrations of individual nuclei from paraffin-embedded and Received 31 July 1997 Revised 1 September 1997 Accepted 16 September 1997 Correspondence to: J Drach, University of Vienna, Department of Internal Medicine I, Division of Clinical Oncology, Wahringer Gurtel 18-20, A-1090 Vienna, Austria methanol-acetic acid-fixed material, thus allowing retrospective analysis of archived material. To delineate numerical chromosomal status of pancreatic carcinomas and to identify chromosomal patterns associated with pancreatic tumour progression, we performed double-hybridization experiments with a panel of four centromeric probes (chromosomes 7, 8, 11 and 18) in 12 primary pancreatic carcinomas and effusion specimens from 25 patients with pancreatic cancer. Gain of chromosomes 7 and 11 and loss of chromosome 18 are frequent findings by metaphase karyotyping in exocrine pancreatic tumours, thus providing the background for FISH analysis of these chromosomes. As chromosome 8 is frequently aberrant in primary and metastatic breast cancer (Roka et al, 1998) and plays a role in prostate cancer progression (Jenkins et al, 1997) , we additionally selected a centromere-specific probe to this chromosome to analyse numerical aberrations of chromosome 8 and their potential significance for pancreatic cancer progression.
In addition to pancreatic adenocarcinomas, four endocrine tumours of the pancreas were analysed by interphase FISH.
Finally, the potential impact of aneuploidy detection by FISH for the identification of pancreatic (micro-)metastatic cells in effusions was evaluated, using an approach previously performed in breast cancer effusions (Roka et al, 1998; Zojer et al, 1997) .
MATERIALS AND METHODS Clinical material
Paraffin-embedded tissue sections from 16 patients undergoing surgery for pancreatic tumours (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) were obtained from the Department of Clinical Pathology (University of Vienna) or the Department of Pathology of the Vienna Donauspital. These specimens comprised eight ductal adenocarcinomas, three periampullary carcinomas, one mucinous cystadenocarcinoma of the pancreas and four endocrine tumours of the pancreas (one gastrin, one insulin, one glucagon and one non-secretory tumour).
Preparation of the primary tumours followed the protocol detailed by Ott et al (1997 FISH procedure and microscopy The FISH protocol followed the standard procedure in our laboratory, as described in detail in a previous report . Directly, fluorescence-labelled alpha satellite probes (Vysis, Downers Grove, IL, USA), specific for the centromeric regions of human chromosomes 7, 8, 11 and 18, were applied. Two-colour FISH was performed using Spectrum Green-labelled probes in combination with Spectrum Orange-labelled probes, with chromosome 18 always being a partner in these combinations.
At least 200 non-overlapping nuclei from each effusion specimen and at least 100 nuclei from each primary tumour were evaluated by fluorescence microscopy (Olympus AH-3 microscope). Photographic documentation was performed using a Kodak Ektachrom 1600 film. In addition, images were acquired using a cooled, charged, coupled device (CCD) camera (Photometrics, Tucson, AZ) mounted on a Zeiss-Axioplan-2 immunofluorescence microscope and the Quips-XL FISH-imaging software (Vysis).
Control specimens and criteria for true aneuploidy Cut-off values for detection of true aneuploidy were calculated as mean signal numbers + three standard deviations of control cells from normal pancreatic tissue (n = 1) and chronic pancreatitis (n = 2) in the case of primary tumours; four effusion specimens from patients with non-malignant diseases served as controls for metastatic effusion cells.
Mean chromosome copy numbers for each tumour specimen and chromosome, which by definition are calculated by dividing the sum of the centromeric signals with the number of nuclei scored, are listed in Tables 1 and 2 . Only nuclei aneuploid by two-colour FISH analysis were considered for calculation of mean copy numbers, and disomic cells (with a pattern of 2/2 signals for the Spectrum Green/ Spectrum Orange probe pair) were skipped from analysis. Concerning the nuclear status of 1/1-signal, 1/2-signal and 2/3-signal cells (or vice versa), only percentages of cells above cut-off were included in the calculation of mean copy numbers. For evaluation of malignant effusions, a cut-off for 3/4-and 4/4-signal cells was established, as a small population of mesothelial cells with this chromosomal pattern was found in control effusions (Fiegl et al, 1996) .
Definitions of modal ploidy and chromosomal imbalances
A modal ploidy status for a tumour specimen was determined if at least three of the four chromosomes showed mean copy numbers in the range of one ploidy unit, allocating the tumour to the corresponding ploidy category (triploidy, tri-tetraploidy, tetraploidy etc., see Tables 1 and 2 ). If all four chromosomes showed mean copy numbers in the range of one ploidy unit, no chromosomal imbalances were indicated (see Table 1 ). In the other case, deviation of the fourth chromosome was indicated as loss or gain. If less than three chromosomes showed mean copy numbers in the defined range, the chromosomal status was termed heterogeneous. Imbalances were predominant in these cases and a distinct ploidy was not evident. Similar criteria for characterization of ploidy and chromosomal imbalances were used in a FISH study of squamous cell carcinomas of the head and neck (Soder et al, 1995) . Furthermore, we analysed three pancreatic carcinoma cell lines (BxPC-3, PANC-1, AsPC-1; all obtained from America Type Culture Collection (ATCC), Rockville, Maryland) using FISH and four centromeric probes. Ploidy estimated on the basis of the FISH results was in good agreement with the ploidy defined by metaphase karyotyping (data provided in the ATCC catalogue).
MYC amplification in aneuploid effusions
In additional experiments, a Spectrum Orange-labelled probe to 8q24 (MYC) was used in combination with a Spectrum Greenlabelled probe to the chromosome 8 centromere. Amplification of the MYC oncogene was defined as the presence of more than 20% of cells with over-representation of MYC signals in relation to chromosome 8 signals (Jenkins et al, 1997) . At least 100 non-overlapping nuclei from each of the ten aneuploid effusion specimens were evaluated. Two effusion cell samples from patients with nonmalignant diseases served as controls for the MYC studies.
Micrometastatic cell detection
In effusion specimens with no detectable aneuploidy by the standard signal scoring procedure (n = 15), 1-2 x 104 nuclei (corresponding to 200 fields with 50-100 cells) were screened for the occurrence of rare aneuploid cells (as detailed previously; Roka et al, 1998) . This is a procedure potentially practicable in the routine setting as, when in situ hybridization is appropriately performed (our laboratory set a minimum standard at 90% hybridization efficiency), it does not take more than 30 min to screen >10 000 nuclei. In this series, two-colour FISH with probe pairs of chromosomes 7/8 and 11/18 was performed, and rare grouped or single cells exhibiting more than four signals and concomitantly showing intranuclear chromosomal heterogeneity (e.g. a signal pattern of 5/2) were considered as unequivocal indicators of malignancy.
RESULTS
Chromosomal status of primary and metastatic pancreatic carcinoma Significant differences were found by comparing the chromosomal status of primary carcinomas (neuroendocrine tumours were excluded from this comparative analysis) with that of metastatic specimens (Tables 1 and 2) . A hyperdiploid modal ploidy status was observed in all primary carcinomas. Concordant gains of signal number for all chromosomes examined were found in 6 of 12 cases and no chromosomal imbalances were indicated in these tumours (P1-P6). In contrast, chromosomal imbalances were identified in all metastatic carcinoma specimens (P < 0.01, X2-test), with chromosome 8 being predominantly affected (see Figure IA) . Chromosomal status of endocrine pancreatic tumours Chromosomal status of endocrine tumours was different to that observed in adenocarcinomas. Chromosomal imbalances with monosomic cell populations were a feature of all four endocrine tumours studied (see Table 1 ). One tumour (N4) was designated haploid because of the predominance of nuclei with monosomy of chromosomes 8, 11 and 18. This finding is in line with a previous study , in which near-haploid clones were identified in two endocrine neoplasms of the pancreas by metaphase karyotyping.
MYC studies Two out of ten malignant pancreatic effusion specimens (20%) showed MYC amplification, as defined in the Materials and methods section. High-level amplification, with a MYCcentromere 8 ratio >2, was observed in effusion E2 (in 32.6% of all nuclei counted, see Figure IB ), which additionally exhibited relative loss of chromosome 8 as indicated in Table 1 . On the other hand, effusion specimen E7 was characterized by a relative gain of chromosome 8 in association with a low level of MYC amplification (with a MYC-centromere 8 ratio of 1.1-2 in 36.9% of nuclei).
In the two control effusions, MYC was over-represented in relation to chromosome 8 in less than 2% of cells evaluated.
FISH as a diagnostic tool to detect micrometastatic cells
We have shown previously that FISH using centromeric probes can improve malignant cell detection in effusions from breast cancer patients (Zojer et al, 1997) . In the present study, we investigated whether or not this is also true Table 2 ).
Previous cytogenetic studies differ in the reported frequencies of gain of 8q in primary pancreatic carcinomas. Solinas-Toldo et al (1996) found gain of 8q in 3 of 27 primary tumours, whereas Fukushige et al (1997) (Dutrillaux et al, 1991) . Endoreduplication, accompanying tumour progression, may also turn monosomy 18 of primary carcinomas into 'relative loss' of chromosome 18, which was indeed observed in one metastatic specimen (E4; relative loss of a chromosome means under-representation in relation to the defined ploidy, whereas monosomy indicates the presence of a single copy of this chromosome).
As chromosome 18 was reported to be frequently aberrant in metaphase cytogenetic studies of pancreatic carcinoma, this chromosome was targeted in all two-colour FISH experiments, excluding MYC studies and studies of micrometastasis detection. Four out of 22 pancreatic tumour specimens (primary tumours and effusion cell samples) exhibited relative loss of chromosome 18, a frequency (18%) lower than the frequency determined by metaphase karyotyping (Johansson et al, 1992; Bardi et al, 1993; Griffin et al, 1994 Griffin et al, , 1995 and approximating the results obtained by comparative genomic hybridization for loss of 18q (Solinas- Toldo et al, 1996; Fukushige et al, 1997) . Loss of 18q may be one mechanism of inactivation of the recently identified tumoursuppressor gene DPC4 (Hahn et al, 1996) .
One particular focus of our work is to establish applications of FISH for diagnostic procedures in the clinical setting Schenk et al, 1997; Zojer et al, 1997) . In this study, we show that hyperdiploidy and intranuclear chromosomal heterogeneity are a constant finding in metastatic pancreatic cancer. This suggests that cohybridization with two centromeric probes may be a useful approach for unequivocal detection of rare (micro) metastatic cells, e.g. in effusions, peritoneal washings or bone marrow specimens.
We tested the implication of interphase FISH for malignant cell detection in effusions from patients with pancreatic cancer by comparing FISH results with data obtained by cytological examination. When extensive evaluation by screening of>10 000 nuclei from each effusion was used, FISH could detect rare aneuploid nuclei in three cytologically negative effusions, thus pointing to malignancy. As we demonstrated previously, FISH is a useful adjunct to cytological examination of effusions from breast cancer patients (Zojer et al, 1997) . This also seems to be true for pancreatic cancer patients, although without statistical confirmation in this series.
Antibodies to cytokeratin are now commonly used for detection of micrometastatic cells in bone marrow of breast, colon and pancreatic cancer patients (Cote et al, 1991; Lindemann et al, 1992; Juhl et al, 1994) . However, it was reported recently that some of these cytokeratin-positive bone marrow cells may actually be normal diploid cells of epithelial origin (Litle et al, 1997) . We therefore propose to use FISH as a tool to unequivocally detect spread of pancreatic cancer to potential metastatic sites (e.g. peritoneal cavity, bone marrow), which may enhance further specification of prognostic subgroups of this disease.
